TransMedics Group, Inc. (TMDX) Stock Forecast & Price Target

TransMedics Group, Inc. (TMDX) has an ST Score of 49.4 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on TMDX is Buy based on 13 analyst ratings. Our own ST Score grades it C+ (49.4/100). This is data, not investment advice — always do your own research.

TransMedics Group, Inc. (TMDX) earns a valuation grade of F, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

TransMedics Group, Inc. (TMDX) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

TransMedics Group, Inc. (TMDX) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

TransMedics Group, Inc. (TMDX) earns a financial strength grade of B-, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for TransMedics Group, Inc. (TMDX) is $96.86 from 13 analysts, which is +0.1% versus the recent price of $86.42.

TransMedics Group, Inc. (TMDX) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.